Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Indications

Metastatic Testicular Tumors: Cisplatin Hexal Hexal is used as part of established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already undergone appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors: Cisplatin Hexal Hexal is used as part of established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already undergone appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Hexal Hexal together with cyclophosphamide. As a single agent, Cisplatin Hexal Hexal is indicated as secondary therapy in patients with metastatic ovarian tumors that are refractory to standard chemotherapy and who have not previously received Cisplatin Hexal Hexal Injection therapy. Advanced Bladder Cancer: Cisplatin Hexal Hexal is indicated as a single agent for patients with transitional cell bladder cancer that is no longer amenable to local treatments such as surgery and/or radiotherapy. Non-Small Cell Lung Carcinoma: Cisplatin Hexal Hexal, in combination with other chemotherapeutic agents, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Cisplatin is a platinum-based compound, and only its cis-isomer is pharmacologically active. It works mainly by forming cross-links within and between DNA strands, which distorts the DNA structure and blocks DNA synthesis. To a lesser degree, it also interferes with protein and RNA synthesis. Cisplatin does not appear to target any specific phase of the cell cycle.

Pregnancy & Breastfeeding

Pregnancy Category D. No adequate, well-controlled studies have been done in pregnant women. Cisplatin has been reported to pass into human breast milk, though it is not yet established whether the drug itself is excreted in human milk.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Cisplatin injection is given by slow intravenous infusion. It must not be given by rapid intravenous injection. Needles or intravenous sets containing aluminum parts that may come into contact with Cisplatin Injection should not be used for preparation or administration, because aluminum reacts with Cisplatin Injection, causing precipitate formation and a loss of potency. Metastatic Testicular Tumors: The usual Cisplatin Injection dose for the treatment of testicular cancer, in combination with other approved chemotherapeutic agents, is 20 mg/m2 IV daily for 5 days per cycle. Metastatic Ovarian Tumors: The usual Cisplatin Injection dose for the treatment of metastatic ovarian tumors, in combination with cyclophosphamide, is 75 to 100 mg/m2 IV per cycle once every 4 weeks (DAY 1). The dose of cyclophosphamide when used in combination with cisplatin is 600 mg/m2 IV once every four weeks (DAY 1). In combination therapy, Cisplatin Injection and cyclophosphamide are administered sequentially. As a single agent, Cisplatin Injection should be given at a dose of 100 mg/m2 IV per cycle once every four weeks. Advanced Bladder Cancer: Cisplatin Injection should be given as a single agent at a dose of 50 to 70 mg/m2 IV per cycle once every 3 to 4 weeks, depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. For heavily pretreated patients, an initial dose of 50 mg/m2 per cycle repeated every 4 weeks is recommended. Non Small Cell Lung Carcinoma: Cisplatin Injection (75 mg/m2) should be given in combination with Paclitaxel (135 mg/m2) every three weeks. Or, as directed by the registered physician.

Side Effects & Interactions